

RECEIVED  
CENTRAL FAX CENTER

SEP 24 2009

AMENDMENTS TO THE CLAIMS

Please amend the claims below by deleting items with a strikeout (i.e. patent) or brackets / double brackets(i.e., [patent] or [[patent]]) and adding items with an underline (i.e. patent).

1. (Currently amended) A method for treating diseases associated with changes of qualitative and/quantitative composition of blood extracellular DNA [[in-particular]] selected from the group comprising: generalized infectious caused by bacteria, diseases caused by fungi and protozoa, atherosclerosis, diabetes, delayed-type hypersensitivity reaction and diseases caused by mutations in somatic cells' genes [[characterized by]], wherein the method comprises introduction [[introducing]] of blood extracellular [[DNA-destroying agent]] DNase enzyme into a systemic blood circulation.
2. (Currently amended) A method according to claim 1 wherein [[DNase]] the blood extracellular DNA destroying agent is a DNase enzyme is introduced into a systemic blood circulation]].
3. (Currently amended) A method according to claim 1 [[which characterized by introducing of DNase enzyme in doses sufficient to provide]] wherein the blood extracellular DNA destroying agent is DNase which is introduced in doses sufficient to

provide a blood extracellular electrophoretic profile change [[, which can be]] as revealed by pulse-electrophoresis.

4. (Currently amended) A method according to claim 1 [[characterized by introducing of DNAase enzyme in doses and regimens which provide blood plasma DNA-hydrolytic activity ,measured in blood plasma, to exceed 150 Kunitz units per liter of plasma during more then 12 hours in total within 24 hours]] wherein the blood extracellular DNA destroying agent is a DNase which is introduced in a dose and regime that results in a DNA hydrolytic activity in blood plasma that exceeds 150 Kunitz units per liter of blood plasma for more than 12 hours within a period of 24 hours.